MERS Fears Prompt Korean Ribavirin Plans
This article was originally published in PharmAsia News
Amid mounting fears over massive spreading of Middle East Respiratory Syndrome (MERS) in South Korea, where the number of confirmed cases totals 35 so far, pharma firms are discussing with the government a possible increase in production of ribavirin, which is known to be partly effective against the virus.
You may also be interested in...
Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.
Amid the highly successful launch of COVID-19 vaccines using the technology by Pfizer/BioNTech and Moderna, South Korean bioventure OliX Pharmaceuticals is diversifying into the mRNA field by establishing a new subsidiary that focuses on R&D into new vaccines and therapeutics using the platform.
Plus deals involving Scynexis/Hansoh, Cend/Qilu, Apollomics/Edison, Apollomics/Iterion, Apollomics/Nuance, Aerami/Chance, Antibe/Nuance, Ildong/Arbormed